CY1114774T1 - 4- [2- (4-μεθυλφαινυλσουλφανυλ) φαινυλο]πιπεριδινη για την αγωγη του συνδρομου ευερεθιστου εντερου (ibs) - Google Patents

4- [2- (4-μεθυλφαινυλσουλφανυλ) φαινυλο]πιπεριδινη για την αγωγη του συνδρομου ευερεθιστου εντερου (ibs)

Info

Publication number
CY1114774T1
CY1114774T1 CY20141100065T CY141100065T CY1114774T1 CY 1114774 T1 CY1114774 T1 CY 1114774T1 CY 20141100065 T CY20141100065 T CY 20141100065T CY 141100065 T CY141100065 T CY 141100065T CY 1114774 T1 CY1114774 T1 CY 1114774T1
Authority
CY
Cyprus
Prior art keywords
methylphenylsulfanyl
piperidine
treatment
bowel syndrome
irritable bowel
Prior art date
Application number
CY20141100065T
Other languages
English (en)
Inventor
Silke Miller
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1114774T1 publication Critical patent/CY1114774T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Η χρήση της 4-[2-(4-μεθυλφαινυλσουλφανυλ)-φαινυλο] πιπεριδίνης ή ενός φαρμακευτικά αποδεκτού άλατος αυτής για την αγωγή του συνδρόμου ευερέθιστου εντέρου.
CY20141100065T 2007-03-20 2014-01-24 4- [2- (4-μεθυλφαινυλσουλφανυλ) φαινυλο]πιπεριδινη για την αγωγη του συνδρομου ευερεθιστου εντερου (ibs) CY1114774T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
EP08758225.0A EP2167085B1 (en) 2007-03-20 2008-06-13 4- [2- (4-methylphenylsulfanyl) phenyl]piperidine for the treatment of irritable bowel syndrome (ibs)

Publications (1)

Publication Number Publication Date
CY1114774T1 true CY1114774T1 (el) 2016-12-14

Family

ID=39575680

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100146T CY1113965T1 (el) 2007-03-20 2013-02-15 4-[2-(4-μεθυλφαινυλσουλφανυλ) φαινυλ] πιπεριδινη με συνδυασμενη σεροτονινη και αναστολη της επαναπροσληψης νορεπινεφρινης για τη θεραπεια της adhd, μελαγχολιας, ανθισταμενης στην αγωγη καταθλιψης ή υπολειμματικων συμπτωματων καταθλιψης
CY20141100065T CY1114774T1 (el) 2007-03-20 2014-01-24 4- [2- (4-μεθυλφαινυλσουλφανυλ) φαινυλο]πιπεριδινη για την αγωγη του συνδρομου ευερεθιστου εντερου (ibs)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100146T CY1113965T1 (el) 2007-03-20 2013-02-15 4-[2-(4-μεθυλφαινυλσουλφανυλ) φαινυλ] πιπεριδινη με συνδυασμενη σεροτονινη και αναστολη της επαναπροσληψης νορεπινεφρινης για τη θεραπεια της adhd, μελαγχολιας, ανθισταμενης στην αγωγη καταθλιψης ή υπολειμματικων συμπτωματων καταθλιψης

Country Status (28)

Country Link
US (2) US20100144788A1 (el)
EP (2) EP2139479B1 (el)
JP (1) JP5388867B2 (el)
KR (1) KR20090125775A (el)
CN (2) CN101646438B (el)
AR (1) AR065798A1 (el)
AU (1) AU2008228639B2 (el)
BR (1) BRPI0808831A2 (el)
CA (1) CA2684556C (el)
CL (1) CL2008000796A1 (el)
CO (1) CO6220957A2 (el)
CY (2) CY1113965T1 (el)
DK (2) DK2139479T3 (el)
EA (1) EA017407B1 (el)
ES (2) ES2399305T3 (el)
HK (1) HK1142007A1 (el)
HR (1) HRP20130049T1 (el)
IL (1) IL200954A (el)
MX (1) MX2009009934A (el)
MY (1) MY163537A (el)
NZ (1) NZ579723A (el)
PL (2) PL2139479T3 (el)
PT (2) PT2139479E (el)
RS (2) RS52676B (el)
SI (1) SI2139479T1 (el)
TW (1) TWI432194B (el)
UA (2) UA99611C2 (el)
WO (1) WO2008113360A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
GEP20166487B (en) * 2010-04-30 2016-06-10 Takeda Pharmaceutical Enteric tablet
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US9311462B1 (en) * 2011-03-04 2016-04-12 Zynga Inc. Cross platform social networking authentication system
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
SG11201810644TA (en) 2016-07-01 2018-12-28 H Lundbeck As Vortioxetine dosing regimes for fast onset of antidepressant effect

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154496C (zh) * 1998-05-22 2004-06-23 伊莱利利公司 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
PL1635828T3 (pl) * 2003-04-04 2008-10-31 H Lundbeck As Pochodne 4-(2-fenyloksyfenylo)-piperydyny lub 1,2,3,6-tetrahydropirydyny jako inhibitory wychwytu zwrotnego serotoniny
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
SI2139479T1 (sl) 2013-04-30
DK2167085T3 (da) 2014-02-03
CN101646438B (zh) 2012-04-11
RS52676B (en) 2013-06-28
CA2684556C (en) 2013-01-08
IL200954A0 (en) 2010-05-17
PL2167085T3 (pl) 2014-08-29
HK1142007A1 (en) 2010-11-26
CO6220957A2 (es) 2010-11-19
PT2167085E (pt) 2014-02-17
CA2684556A1 (en) 2008-09-25
UA99611C2 (ru) 2012-09-10
PL2139479T3 (pl) 2013-05-31
UA97660C2 (ru) 2012-03-12
ES2399305T3 (es) 2013-03-27
WO2008113360A2 (en) 2008-09-25
TWI432194B (zh) 2014-04-01
JP5388867B2 (ja) 2014-01-15
PT2139479E (pt) 2013-02-20
IL200954A (en) 2014-12-31
US20100144788A1 (en) 2010-06-10
AR065798A1 (es) 2009-07-01
EP2139479A2 (en) 2010-01-06
RS53138B (en) 2014-06-30
MY163537A (en) 2017-09-15
ES2445400T3 (es) 2014-03-03
CL2008000796A1 (es) 2008-09-26
CN101674830B (zh) 2012-05-09
CN101646438A (zh) 2010-02-10
TW200848032A (en) 2008-12-16
BRPI0808831A2 (pt) 2014-08-26
US20100137366A1 (en) 2010-06-03
EP2167085B1 (en) 2013-12-25
HRP20130049T1 (hr) 2013-02-28
AU2008228639A1 (en) 2008-09-25
EP2167085A1 (en) 2010-03-31
DK2139479T3 (da) 2013-02-11
EA017407B1 (ru) 2012-12-28
NZ579723A (en) 2011-07-29
AU2008228639B2 (en) 2012-12-13
MX2009009934A (es) 2009-09-24
EP2139479B1 (en) 2012-12-12
US8507526B2 (en) 2013-08-13
CN101674830A (zh) 2010-03-17
CY1113965T1 (el) 2016-07-27
EA200970871A1 (ru) 2010-04-30
KR20090125775A (ko) 2009-12-07
WO2008113360A3 (en) 2008-11-13
JP2010521502A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
CY1114774T1 (el) 4- [2- (4-μεθυλφαινυλσουλφανυλ) φαινυλο]πιπεριδινη για την αγωγη του συνδρομου ευερεθιστου εντερου (ibs)
CY1122812T1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
CY1118004T1 (el) Αναστολεις cdk
CY2017038I1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων
CY1117978T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a
CY1113352T1 (el) Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους
NL300998I2 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
CY1119232T1 (el) Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης
CR11819A (es) Compuestos de isoindolina 5-sustituidos
EA201070786A1 (ru) Бензофуропиримидиноны
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
EA201170872A1 (ru) Ингибиторы протеинкиназы
CU20110213A7 (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
CL2007003158A1 (es) Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
BRPI0812923A2 (pt) Derivados de piperidina/piperazina
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
EA200801414A1 (ru) Кальцилитические соединения
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CY1113622T1 (el) Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
CY1114020T1 (el) 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης